|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 471/04 | (2006.01) |
| A61K 31/4523 | (2006.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 27/00 | (2006.01) |
| (11) | Number of the document | 3619208 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18724753.1 |
| Date of filing the European patent application | 2018-04-30 | |
| (97) | Date of publication of the European application | 2020-03-11 |
| (45) | Date of publication and mention of the grant of the patent | 2023-06-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/030144 |
| Date | 2018-04-30 |
| (87) | Number | WO 2018/204236 |
| Date | 2018-11-08 |
| (30) | Number | Date | Country code |
| 201762492571 P | 2017-05-01 | US |
| (72) |
DABROS, Marta , US
THALLADI, Venkat R. , US
NZEREM, Jerry , US
KLEINSCHEK, Melanie A. , US
CRATER, Glenn D. , US
|
| (73) |
Theravance Biopharma R&D IP, LLC ,
901 Gateway Boulevard, South San Francisco, CA 94080,
US
|
| (54) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND |
| CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND |